Prevention of Heart Damage During Anthracycline Cancer Chemotherapy
Prevention of Heart Damage During Anthracycline Cancer Chemotherapy
批准号:
nhmrc : GNT1145776
负责人:
A/Pr Benedetta Sallustio
金额:
$32.72万
依托单位国家:
澳大利亚
项目类别:
Project Grants
财政年份:
2018
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2018-01-01 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Doxorubicin is an effective medicine widely used for the treatment of cancer. However, it can cause heart damage, which not only creates a new health problem, but also limits the length of doxorubicin treatment cancer patients can receive, and therefore the likelihood of cancer cure. Preventing heart damage by doxorubicin is therefore important to improve overall cancer cure rates and patient health. This study aims to develop new medications to prevent heart damage during cancer chemotherapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Prevention of Heart Damage During Anthracycline Cancer Chemotherapy
-
批准号:nhmrc : 1145776
-
项目类别:Project Grants
-
资助金额:$22.12万
-
财政年份:2018
-
负责人:A/Pr Benedetta Sallustio
-
依托单位:
Pharmacogenomics of renal transplantation
-
批准号:nhmrc : 565038
-
项目类别:NHMRC Project Grants
-
资助金额:$23.89万
-
财政年份:2009
-
负责人:A/Pr Benedetta Sallustio
-
依托单位:
Novel mechanisms of genotoxicity: bioactivation of carboxylic acid drugs by UDP-glucuronosyltransferases
-
批准号:nhmrc : 250320
-
项目类别:NHMRC Project Grants
-
资助金额:$13.65万
-
财政年份:2003
-
负责人:A/Pr Benedetta Sallustio
-
依托单位:
国内基金
海外基金
e-Heart仿真平台及关键技术研究
-
批准号:60571025
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2005
-
负责人:王宽全
-
依托单位: